Latest News and Press Releases

Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024  InFoods IBS Positive Clinical Data to be Presented...

Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) --...

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the...

Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built...

Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share...

Over 80% of gastric cancers are attributed to H. pylori bacterial infection Gastric cancer is the third most common cause of cancer related death in the world ...

IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th...

Biomerica remains on track for inFoods® IBS national rollout during calendar 2024, and expects strong product revenue growth during national rolloutVeteran Vice President of Sales and National...

Biomerica Reports First Quarter 2024 Financial Results. Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024

Biomerica Reports First Quarter 2024 Financial Results. Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024